Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | September 30, 2026 | October 03, 2026 |
| GE HealthCare Technologies Inc.GEHC · Entity 1711 | Director · President and CEO | September 03, 2026 | September 04, 2026 |
| GENERAL ELECTRIC COGE · Entity 2813 | Senior Vice President | March 01, 2022 | March 04, 2022 |
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | Director · President & CEO | September 02, 2021 | September 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 74,077.176 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 560.897 · Balance 74,077.176 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
GE HealthCare Technologies Inc.
Report date September 03, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 241,606 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Tax withholding · Disposed 6,303 · Balance 241,606 F1: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
GENERAL ELECTRIC CO
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,443 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 14,443 · Balance 14,443 F1: 1 for 1 F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.23 · Expires 2032-03-01 | Direct | 63,044 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 63,044 · Balance 63,044 F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date |
Filing footnotes · ownership attribution and instrument terms
F1: 1 for 1
F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date September 02, 2021 · Filed September 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,713 |
Ending reported balance
After 2021-09-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-09-02 · Exercise / conversion · Acquired 71,829 · Balance 288,542 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Row 2 · 2021-09-02 · Sale · Disposed 71,829 · Balance 216,713 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.34 to $76.465 per share of common stock. Row 3 · 2021-09-03 · Exercise / conversion · Acquired 46,605 · Balance 263,318 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Row 4 · 2021-09-03 · Sale · Disposed 46,605 · Balance 216,713 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.40 to $76.09 per share of common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.88 · Expires 2022-03-06 | Direct | 46,605 |
Reported balance
After 2021-09-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-09-02 · Exercise / conversion · Disposed 71,829 · Balance 46,605 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date. F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.88 · Expires 2022-03-06 | Direct | 0 |
Reported balance
After 2021-09-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-09-03 · Exercise / conversion · Disposed 46,605 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date. F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
F2: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.34 to $76.465 per share of common stock.
F3: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.40 to $76.09 per share of common stock.
F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date.
F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015.
F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2020 Filed Mar 27, 2020 20:34 UTC Amendment | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 138,143 | $0.00 Strike: $43.39 | $0.00 |
DisclosureSEC source: 0001209191-20-021394 · doc4a.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,143 Underlying: Common Stock · 138,143 shares Expires 2028-03-13 F1 · shares: This amendment to the Form 4, originally filed on March 17, 2020, is being filed to correct the number of options and shares awarded and beneficially owned due to an administrative error in the original filing. F2 · derivative.exercise_date: The grant will vest as to one-third of the shares on the first anniversary of the grant date of 3/13/2020 and thereafter in monthly installments through the following twenty-four months. F1 · derivative.underlying_shares: This amendment to the Form 4, originally filed on March 17, 2020, is being filed to correct the number of options and shares awarded and beneficially owned due to an administrative error in the original filing. F1 · balance_after: This amendment to the Form 4, originally filed on March 17, 2020, is being filed to correct the number of options and shares awarded and beneficially owned due to an administrative error in the original filing. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:47 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 32,316 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001209191-20-013942 · doc4.xml · derivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,316 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date which is March 1, 2012 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the 3rd anniversary of the grant date. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:47 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 32,316 | $55.68 | $1,799,332.26 |
DisclosureSEC source: 0001209191-20-013942 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,575 F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $54.32 to $57.49. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:47 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 32,316 | $13.89 | $448,869.24 |
DisclosureSEC source: 0001209191-20-013942 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,540 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · derivative · entry 12 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,316 Underlying: Common Stock · 3,540 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F5 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date which is March 1, 2012 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the 3rd anniversary of the grant date. Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 21,960 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · derivative · entry 11 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,856 Underlying: Common Stock · 21,960 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F5 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date which is March 1, 2012 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the 3rd anniversary of the grant date. Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 3,540 | $57.12 | $202,190.29 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · nonDerivative · entry 8 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,575 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $56.50 to $58.43. Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 3,540 | $13.89 | $49,170.60 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · nonDerivative · entry 7 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 21,960 | $57.12 | $1,254,265.16 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · nonDerivative · entry 6 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,575 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $56.50 to $58.43. Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 21,960 | $13.89 | $305,024.40 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · nonDerivative · entry 5 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 37,704 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · derivative · entry 10 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,816 Underlying: Common Stock · 37,704 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F5 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date which is March 1, 2012 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the 3rd anniversary of the grant date. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 37,704 | $58.21 | $2,194,923.28 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · nonDerivative · entry 4 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,575 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · price: The price shown above represents the weighted average price of the shares sold. The range of the sale prices was $57.57 to $58.86. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 37,704 | $13.89 | $523,708.56 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,344 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · derivative · entry 9 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,520 Underlying: Common Stock · 20,344 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F5 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date which is March 1, 2012 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the 3rd anniversary of the grant date. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 20,344 | $59.56 | $1,211,729.33 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,575 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $59.50 to $60.29. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 20,344 | $13.89 | $282,578.16 |
DisclosureSEC source: 0001209191-20-012619 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:35 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 16,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010160 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,575 F3 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019 under the March 13, 2019 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2020 at 97% of target, the first anniversary of the grant date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:35 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 15,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010160 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,259 F2 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019 under the March 13, 2018 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2020 at 97% of target, the second anniversary of the grant date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:35 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 27,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010160 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,747 F1 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019, at least 9% and up to a maximum of 33% cumulative increase in annual revenue over the 2016 fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 34% of the shares will vest on March 13, 2020 at 150% of target, the third anniversary of the grant date. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 22:59 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,018.268 | $62.95 | $189,999.97 |
DisclosureSEC source: 0000014272-20-000058 · wf-form4_158085715087429.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,204.285 Underlying: Common Stock, $0.10 par value · 3,018.268 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 23:48 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 564.73 | $64.19 | $36,250.02 |
DisclosureSEC source: 0000014272-20-000014 · wf-form4_157809526619471.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,030.097 Underlying: Common Stock, $0.10 par value · 564.73 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 20:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 714.849 | $50.71 | $36,249.99 |
DisclosureSEC source: 0000014272-19-000174 · wf-form4_157004943560648.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,312.496 Underlying: Common Stock, $0.10 par value · 714.849 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001209191-19-049009 · doc4.xml · derivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,864 Underlying: Common Stock · 250,000 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date which is March 1, 2012 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the 3rd anniversary of the grant date. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 250,000 | $60.55 | $15,137,150.00 |
DisclosureSEC source: 0001209191-19-049009 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,017 F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $60.545 to $60.705. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 250,000 | $13.89 | $3,472,500.00 |
DisclosureSEC source: 0001209191-19-049009 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:12 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 767.536 | $45.35 | $34,807.76 |
DisclosureSEC source: 0000014272-19-000138 · wf-form4_156210193771325.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,412.492 Underlying: Common Stock, $0.10 par value · 767.536 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 681.199 | $47.71 | $32,500.00 |
DisclosureSEC source: 0000014272-19-000092 · wf-form4_155423745968544.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,473.549 Underlying: Common Stock, $0.10 par value · 681.199 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units/Contract Stock · Derivative | 368 | $56.14 Strike: $0.00 | $20,659.52 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · derivative · entry 14 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,750 Underlying: Common Stock · 368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/14/16 of which the third installment vested on 3/14/19 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F5 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/14/16 of which the third installment vested on 3/14/19 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F5 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/14/16 of which the third installment vested on 3/14/19 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 15,292 | $56.14 | $858,492.88 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · nonDerivative · entry 9 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,017 Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 368 | $56.14 | $20,659.52 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · nonDerivative · entry 8 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,309 Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 368 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · nonDerivative · entry 7 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units/Contract Stock · Derivative | 20,390 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · derivative · entry 13 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,118 Underlying: Common Stock · 20,390 shares Expires not disclosed F4 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2019 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F4 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2019 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F4 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2019 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units/Contract Stock · Derivative | 258 | $55.91 Strike: $0.00 | $14,424.78 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · derivative · entry 12 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,728 Underlying: Common Stock · 258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/18 of which the first installment vested on 3/13/19 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F3 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/18 of which the first installment vested on 3/13/19 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F3 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/18 of which the first installment vested on 3/13/19 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units/Contract Stock · Derivative | 290 | $55.91 Strike: $0.00 | $16,213.90 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · derivative · entry 11 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,986 Underlying: Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/17 of which the second installment vested on 3/13/19 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F2 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/17 of which the second installment vested on 3/13/19 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F2 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/17 of which the second installment vested on 3/13/19 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 91,249 | $0.00 Strike: $55.91 | $0.00 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · derivative · entry 10 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,249 Underlying: Common Stock · 91,249 shares Expires 2027-03-13 F1 · derivative.exercise_date: The grant will vest as to one-third of the shares on the first anniversary of the grant date of 3/13/2019 and thereafter in monthly installments through the following twenty-four months. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 11,687 | $55.91 | $653,420.17 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · nonDerivative · entry 6 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,309 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 6,215 | $55.91 | $347,480.65 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · nonDerivative · entry 5 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,996 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 258 | $55.91 | $14,424.78 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · nonDerivative · entry 4 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,211 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 258 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 290 | $55.91 | $16,213.90 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,211 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019749 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 21:45 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 14,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011116 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,211 F3 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018 under the March 13, 2018 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2019 at 89.5% of target, the first anniversary of the grant date. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 21:45 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 26,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011116 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,899 F2 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 33% of the shares will vest on March 13, 2019 at 150% of target, the second anniversary of the grant date. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 21:45 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 35,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011116 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,985 F1 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 34% of the shares will vest on March 14, 2019 at 150% of target, the third anniversary of the grant date. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:54 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,708.158 | $49.89 | $185,000.00 |
DisclosureSEC source: 0000014272-19-000042 · wf-form4_154940367492090.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,792.35 Underlying: Common Stock, $0.10 par value · 3,708.158 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:28 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 625.24 | $51.98 | $32,499.98 |
DisclosureSEC source: 0000014272-19-000010 · wf-form4_154655086599016.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,760.751 Underlying: Common Stock, $0.10 par value · 625.24 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2018 Filed Oct 3, 2018 01:41 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 523.518 | $62.08 | $32,500.00 |
DisclosureSEC source: 0000014272-18-000185 · wf-form4_153853088473297.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,135.511 Underlying: Common Stock, $0.10 par value · 523.518 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2018 Filed Jul 4, 2018 01:29 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 587.279 | $55.34 | $32,500.02 |
DisclosureSEC source: 0000014272-18-000154 · wf-form4_153066777352556.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,611.993 Underlying: Common Stock, $0.10 par value · 587.279 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 20:35 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 513.834 | $63.25 | $32,500.00 |
DisclosureSEC source: 0000014272-18-000099 · wf-form4_152278769410625.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,926.581 Underlying: Common Stock, $0.10 par value · 513.834 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units/Contract Stock · Derivative | 343 | $54.15 Strike: $0.00 | $18,573.45 |
DisclosureSEC source: 0001209191-18-021783 · doc4.xml · derivative · entry 4 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,276 Underlying: Common Stock · 343 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/23/15 of which the third installment vested on 3/23/18 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F1 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/23/15 of which the third installment vested on 3/23/18 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F1 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/23/15 of which the third installment vested on 3/23/18 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.